Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

3.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.2K
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

349
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
349
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

63
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
63
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

38
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
38
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

71
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
71
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

40
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
40

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Vericiguat therapy reduces arrhythmic events in heart failure patients with cardiac implantable electronic devices.

Heart rhythm·2026
Same author

SGLT2 Inhibitors in Elderly Patients: Clinical Perspectives from Metabolic and Cardiorenal Protection to Implementation.

Journal of clinical medicine·2026
Same authorSame journal

[Ranolazine: established indications and emerging therapeutic potential].

Giornale italiano di cardiologia (2006)·2026
Same authorSame journal

[Green paper ANMCO: Environmental sustainability in cardiology: a shared commitment of healthcare professionals].

Giornale italiano di cardiologia (2006)·2026
Same author

Semaglutide for the Silent Phenotype: A Translational Signal in Obesity-Driven HFpEF.

The American journal of cardiology·2026
Same author

Bempedoic acid for prevention of atherosclerotic cardiovascular disease: from trials to clinical practice.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2026

相关实验视频

Updated: Sep 16, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.7K

[心血管风险分层的演变]

Andrea Matteucci1, Stefania Angela Di Fusco1, Alessandro Aiello1

  • 1U.O.C. Cardiologia Clinica e Riabilitativa, Presidio Ospedaliero San Filippo Neri - ASL Roma 1, Roma.

Giornale italiano di cardiologia (2006)
|July 7, 2025
PubMed
概括
此摘要是机器生成的。

心血管风险分层正在从静态模型演变为动态,个性化的模型. 新的工具和生物标志物使得早期的有针对性的预防能够获得更好的长期结果.

更多相关视频

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.0K
Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

1.1K

相关实验视频

Last Updated: Sep 16, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.7K
Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression
13:07

Optical Coherence Tomography Based Biomechanical Fluid-Structure Interaction Analysis of Coronary Atherosclerosis Progression

Published on: January 15, 2022

4.0K
Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

1.1K

科学领域:

  • 心脏病学 心脏病学
  • 预防医学 预防医学
  • 医疗信息学 医疗信息学

背景情况:

  • 心血管疾病的预防严重依赖于风险分层.
  • 传统的风险评估模型正在更新,以反映新的数据和方法.
  • 个性化医疗正在改变心血管风险管理.

研究的目的:

  • 描述心血管风险分层从静态模型转向动态和个性化模型的转变.
  • 突出新工具和技术在改善风险评估中的作用.
  • 强调向风险分层的持续概念的转变.

主要方法:

  • 使用最新的风险评估工具,如SCORE2,SCORE2-OP,SCORE2-糖尿病和SMART2.2等.
  • 将临床,人口和地理变量纳入风险估计.
  • 采用先进的非侵入性成像 (例如,冠状动脉评分) 和生物标志物用于早期风险检测.

主要成果:

  • 较新的模型提供了更准确的,特定于背景的绝对心血管风险估计.
  • 先进的技术可以在看似健康的个体中发现"隐藏"的风险.
  • 综合多样化的数据,使得风险评估更精细,更及时.

结论:

  • 心血管风险分层变得越来越动态,综合和个性化.
  • 早期和有针对性的预防策略是通过精确的风险评估来实现的.
  • 改善风险分层导致心血管事件减少和更好的长期结果.